now approved

With a different way to treat cGVHD,1-3

rezurock can help patients

ROCK ON

For patients with cGVHD aged 12 years after failure of at least 2 prior lines of systemic therapy.1

REZUROCK is the first and only selective ROCK2 inhibitor for the treatment of cGVHD that gives patients the chance to be themselves again.1

For patients with cGVHD aged ≥12 years after failure of at least 2 prior lines of systemic therapy.1

REZUROCK is the first and only selective ROCK2 inhibitor for the treatment of cGVHD that gives patients the chance to be themselves again.1

Belumosudil (REZUROCK™) has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A systemic option for steroid-refractory cGVHD.4,a

REZUROCK demonstrated efficacy in a broad range of patients with cGVHD1

The ORRb was 75% at the recommended dose of 200 mg once daily (n=65) in the pivotal ROCKstar study.

EXPLORE EFFICACY

aNCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

bBased on a final analysis by the FDA (n=65).

REZUROCK demonstrated a well-tolerated safety profile in 2 multicenter clinical studies1,5,6

The safety profile of REZUROCK supports its use in a diverse population of patients with cGVHD.

EXPLORE Safety
and tolerability

aNCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

bBased on a final analysis by the FDA (n=65).

A treatment that specifically addresses both the

Inflammation and the fibrosis

associated with cGVHD1-3

Discover AN INNOVATIVE
dual inhibitor
See How REZUROCK works

cGVHD, chronic graft-versus-host disease; FDA, US Food and Drug Administration; MOA, mechanism of action; NCCN, National Comprehensive Cancer Network®; ORR, overall response rate; QOL, quality of life; ROCK2, rho-associated coiled-coil—containing protein kinase-2.

References: 1. REZUROCK. Package insert. Kadmon Pharmaceuticals, LLC; 2021. 2. Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111(47):16814-16819. doi:10.1073/pnas.1414189111 3. Flynn R, Paz K, Du J, et al. Targeted rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17):2144-2154. doi:10.1182/blood-2015-10-678706 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation (HCT): Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease. V.4.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed September 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org 5. Cutler CS, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: the ROCKstar study. Blood. 2021;blood.2021012021. doi:10.1182/blood.2021012021 6. Jagasia M, Lazaryan A, Bachier DR, et al. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J Clin Oncol. 2021;39(17):1888-1898. doi:10.1200/JCO.20.02754 7. Kurosawa S, Oshima K, Yamaguchi T, et al. Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(10):1749-1758. doi:10.1016/j.bbmt.2017.06.011